lintuzumab vedotin

Lintuzumab vedotin is an antibody-drug conjugate (ADC) consisting of the humanized anti-CD33 monoclonal antibody lintuzumab (HuM195) linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Developed by Seattle Genetics, it targets CD33 (Siglec-3), a cell surface receptor expressed on the blasts of approximately 90% of patients with acute myeloid leukemia (AML). Upon binding to CD33 and subsequent internalization, the MMAE payload is released into the lysosomal compartment, where it then enters the cytosol to inhibit tubulin polymerization. This action leads to G2/M phase cell cycle arrest and subsequent apoptosis of the leukemia cells. Although it demonstrated potent anti-leukemic activity in preclinical models, its clinical development was largely superseded by next-generation CD33-targeted ADCs, such as vadastuximab talirine (SGN-CD33A), which utilized different cytotoxic payloads.

Other names

HuM195-MMAEHuM-195-MMAEHuM 195-MMAEHuM195-vcMMAEHuM-195-vcMMAEHuM 195-vcMMAEanti-CD33-MMAE ADCanti-CD-33-MMAE ADCanti-CD 33-MMAE ADC